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Abstract 
Objective To evaluate the prevalence of epilepsy and to assess secular trends in the 
life-time prevalence of epilepsy in rural China over a 12-year period.  
Methods In 2000-2002 and in 2012-2013, two independent cross-sectional 
epidemiological surveys, using an identical protocol, were conducted in rural areas in 
Shanghai, Shanxi Province, and Ningxia Hui Autonomous Region. The survey 
procedure included two stages: screening and ascertaining epilepsy cases in the target 
population. The initial screening was conducted by trained rural physicians and the 
diagnosis was confirmed or rejected by neurologists in the second stage. The age 
structure of the Chinese rural population in 2012 was used for standardization.  
Results The 2000-2002 survey included 32,680 people and the standardized life-time 
prevalence was 6.79‰ (95% confidence interval [CI], 5.96-7.74‰). In 2012-2013, in 
a population of 16,873, the standardized life-time prevalence rate was 3.97‰ (95%CI, 
3.13-5.04‰). The overall prevalence decreased by 41% over 12 years (P<0.001). The 
decreasing trend of life-time prevalence was found in each site and nearly all age-
specific groups.  
Conclusions Life-time prevalence of epilepsy seems to have significantly decreased 
in rural China over a 12-year period. We hypothesize that it may be attributed to 
decreased incidence and increased premature mortality.  
Introduction 
Epilepsy affects up to 70 million people worldwide.1 More than 80% of the global 
burden of epilepsy is found in resource-poor settings where the condition is largely 
untreated.2 In China, epilepsy prevalence estimates ranged from 0.90‰ to 8.50‰ 
during the 1980s and 2000s.3 In 2003, it was estimated there were at least 9 million 
people with epilepsy in China.3 In the last two decades there has been significant 
economic growth, rapid urbanization and demographic changes with an increase aging 
of the population. Epilepsy awareness has also increased. These social changes may 
have impacted epilepsy prevalence.  
Recently, a systematic review4 using modeling suggested that the life-time 
epilepsy prevalence in China increased substantially between 1990 and 2015, with 
prevalence having more than doubled and the number of people with epilepsy more 
than tripled (with an overall increase in the Chinese population). This is not consistent 
with the notion that epilepsy is a condition with a generally low prevalence.5 A recent 
review focusing on epilepsy in Asia only referenced the few Chinese epidemiological 
surveys published in English, omitting many more studies reported in Chinese, thus 
introducing a publication bias.6 
In 2000-2002 and in 2012-2013, we conducted two cross-sectional population-
based surveys to determine the life-time prevalence of epilepsy with identical 
protocols in the same areas of rural China. It offered us the opportunity to re-examine 




Study design and participants 
We applied a multi-stage random cluster sampling based on Chinese census units 
in rural areas in Shanghai, Shanxi province and Ningxia Hui Autonomous Region, 
which represented not only different geographical areas (east [Shanghai], middle 
[Shanxi] and west [Ningxia]), and multiple ethnicities (Han [Shanghai and Shanxi] 
and Hui [Ningxia]), but also diverse economic levels (high [Shanghai], middle 
[Shanxi] and low [Ningxia] (Figure 1). Participants were enrolled if they met 
residency criteria: living in the area regardless of household registration for more than 
a month. Those with household registration were also enrolled if they had temporarily 
left the area for less than 1 month at the time of the survey. Lists of residents were 
extracted from the local population registration system. Guardians or relatives of 
children younger than 15 years and of people aged over 70 years, as well as those with 
learning disabilities, were interviewed to obtain accurate data.  
 
Survey procedure  
The survey procedure included two stages of screening and ascertaining epilepsy 
cases in the target population. At the screening stage, well-trained local village 
physicians and health workers performed door-to-door interviews to enroll 
participants to complete the screening questionnaire. The questionnaire was based on 
the WHO screening questionnaires previously used in China and on the International 
Community-based Epilepsy Research Group (ICBERG) screening instrument with 
specificity (78.5%) and sensitivity (100%) previously validated in China.7 In the 
diagnosis-ascertaining stage, “definitive” or “suspected” epilepsy cases reported from 
the first stage were reviewed in person by a supervising neurologist from the 
provincial hospital in the study area. Neurologists confirmed or refuted the diagnosis 
of epilepsy based on medical history, clinical symptoms and examination of each 
individual who had screened positive. Difficult cases were resolved by consensus 
after an expert panel discussion.  
The first epidemiological survey was carried out in rural areas of Shanghai, 
Shanxi province, and Ningxia Hui Autonomous Region during 2000 and 2002. During 
2012 and 2013, we carried out the second survey in the same general areas with 
identical protocol and questionnaire as used in the 2000-2002 survey. Survey 
populations in each site in the two surveys did not necessarily overlap but were in 
adjacent communities. Some datasets from the first survey were previously analyzed 
and reported,3 but for this study we obtained the raw data and re-analyzed it. 
 
Operational definitions 
Following guidelines for epidemiologic studies,8,9 epilepsy was defined as having 
two or more epileptic seizures occurring >24 hours apart, unprovoked by any 
immediate identified cause. Individuals with only febrile seizures or only neonatal 
seizures were excluded. 
The concept of prevalence in this study refers to the life-time prevalence of 
epilepsy, which is the proportion of the population with a diagnosis of epilepsy from 
birth to the time of the investigation, regardless of treatment status or recentness of 
seizures. Different from the prevalence of active epilepsy, this includes individuals 




The minimal sample size for each site was estimated at 2052, using PASS version 
11.0 Software and the formula for population surveys. We used an expected 
prevalence of 2.89‰ provided by a systematic review10, a 95% confidence interval 
(CI) and a 5‰ expected CI Width (two-sided).  
The life-time prevalence rate of epilepsy was estimated as the number of people 
having had epilepsy at any point in their lifetime, divided by the number of 
participants, and described as “number ‰” with 95%CI. This was estimated for the 
entire population, and for age group and site. The standardized prevalence was 
calculated by the direct method using the population age structure reported in the 
2012 national population census as the reference population.11 Chi-squared tests or 
Fisher’s exact tests were used to explore the differences between the prevalence rates 
in the two surveys. 
The 95% CIs were derived from the Wilson Score tests.12 P-values and 95% CIs 
were estimated in a two-tailed fashion. Differences were considered to be statistically 
significant at p<0.05. All statistical analyses were performed using SPSS 22.0 
software for Windows (SPSS Inc., Chicago, IL, USA).  
 
Results 
The 2000-2002 survey included 32,680 people of whom 224 were confirmed as 
having definite epilepsy (see Table1), providing a standardized life-time prevalence of 
6.79‰ (95%CI, 5.96-7.74‰). The 2012-2013 survey included a population of 16,873, 
and identified 71 people with a definite history of epilepsy, yielding a standardized 
life-time prevalence of 3.97‰ (95%CI, 3.13-5.04‰), a decrease of 41% over 12 years 
(P<0.001). In the 2000-2002 survey, the standardized life-time prevalence was 5.75‰ 
(95%CI, 4.49-7.37‰) in Shanghai, 6.13‰ (95%CI, 4.80-7.84‰) in Shanxi, and 
7.48‰ (95%CI, 6.07-9.22‰) in Ningxia. The standardized life-time prevalence 12-
years later decreased by 40% in Shanghai and by 16% in Shanxi. In Ningxia it 
decreased by 52% (P<0.001) (Table 1).  
 
Table 1 Crude and standardized life-time epilepsy prevalence in 2000-2002 and 2012-2013 surveys  
 2000-2002 survey 2012-2013 survey  














prevalence *, ‰ 
(95%CI) 
P value** 
Shanghai 10777 65 6.03 (4.74-7.68) 5.75 (4.49-7.37) 3454 13 3.76 (2.20-6.43) 3.47 (1.99-6.06) 0.105 
Shanxi 10273 60 5.84 (4.54-7.51) 6.13 (4.80-7.84) 4454 23 5.16 (3.44-7.74) 5.16 (3.44-7.74) 0.479 
Ningxia 11630 99 8.51 (7.00-10.35) 7.48 (6.07-9.22) 8965 35 3.90 (2.81-5.42) 3.57 (2.53-5.03) <0.001 
Total 32680 224 6.85 (6.02-7.81) 6.79 (5.96-7.74) 16873 71 4.21(3.34-5.30) 3.97(3.13-5.04) <0.001 
*Standardized prevalence was calculated by the direct method according to the Chinese rural population age structure in 2012. 
** Comparison of standardized prevalence rates between two surveys. 
 
Figure 1 shows that most age-specific prevalence rates were lower in the 2012-2013 survey than previously. There was a significant decrease 
in the 40-59 years’ group in Shanghai (from7.11‰ to 1.87‰, p=0.049), in those aged 10-19 years (from 10.54‰ to 4.05‰, p=0.019) and 20-39 
years (from 9.73‰ to 3.68‰, p=0.001) in Ningxia, and in those aged 10-19 years (from 8.15‰ to 3.56‰, p=0.015) and 20-39 years (from 
6.44‰ to 3.72‰, p=0.020) in all participants. The biggest difference in 
prevalence in Shanxi, Ningxia and overall were found in the 10-19 years group, but in 
Shanghai the biggest difference was in the group aged 40-59 years. Different from 




We ascertained trends of life-time prevalence of epilepsy over a 12-year period 
through two epidemiological surveys using identical protocols. The life-time 
prevalence decreased significantly over the period and this was seen in all sites and 
most age-specific groups. 
There are few longitudinal studies of secular changes of epilepsy prevalence. 
Work conducting decennial censuses in Minnesota from 1935 to 1984 showed that the 
life-time prevalence increased with each subsequent census.13 A population of about 
6000 people in Britain was assessed 10 years apart, and life-time prevalence increased 
slightly but without statistical significance.14 In China, two door-to-door surveys 
conducted in 2000 and 2004 in the same six areas of rural China reported a decrease 
in life-time prevalence, though not statistically significant.15 Recently, a systematic 
review4 estimated the life-time epilepsy prevalence trends in China using modeling; 
the life-time prevalence estimations increased by nearly 260% in a 15- year period. 
This review has limitations. Firstly, the selected population-based surveys had large 
variations in study design, screening instruments, diagnostic criteria, and sampling 
locations, thus rendering the data unsuitable for pooling due to heterogeneity. 
Secondly, prevalence rates in 1990, 2000, and 2015 were not similar to 
contemporaneously reported multi-center population-based studies in China.3,16–18 
Thirdly, among total participants, only about 5% specific data points based on age, sex and location provided the information on life-time 
epilepsy prevalence. These small numbers were used, leading to wide CIs in age groups especially in 2015. This suggests that the large increase 
in life-time epilepsy prevalence is in doubt.  
We searched Pubmed and Chinese Databases for reports in either English or Chinese languages on door-to-door epidemiological surveys 
involving at least life-time prevalence in China since 2000 and extracted data when available (Table 2). In the table, though very few studies 
were conducted in the same areas, general downward trends in life-time prevalence, active prevalence and incidence can be seen.  
 
Table 2 Literature review of door-to-door surveys for life-time epilepsy prevalence in China from 2000 to 2013 


















Qin et al.(2001)33 Henan 2000 12457 rural WHO&ICBERG 
SQ 
common-2 all 4.7 3.5 32.1 
Du et al.(2002)34 Ningxia 2000 11630 rural WHO&ICBERG 
SQ 
common-2 all 8.51 6.7 25.8 
Xu et al.(2002)35 Shanxi 2000 10273 rural WHO&ICBEGR 
SQ 
ILAE 1993 all 5.8 3.3 38.9 
Wang et al.(2002)36 Heilongjiang 2000 10151 rural SQ NS all 7.98 NS 29.55 
Zhang et al(2005)37 Jiangsu 2000-2001 11895 rural SQ NS all 7.83 NS 53.40 
Ding et al.(2004)38 Shanghai 2002 10777 rural WHO&ICBEGR 
SQ 
ILAE 1993 all 6.03 3.80 NS 
Huang et al.(2008)39 Ningxia 2003 8316 rural WHO&ICBEGR 
SQ 
common-2 all 8.3 6.5 28.8 
Wang et al.(2008)15 Heilongjiang/
Ningxia/Hena
2004 51644 rural WHO&ICBEGR 
SQ 
ILAE 1993 all 6.2 4.5 NS 
NS: not stated; WHO: World Health Organization; ILAE: International League against Epilepsy; ICBERG: International Community-based 
Epilepsy Research Group; SQ: screening questionnaire; t, total; r, rural; u, urban; y: year. 
Active prevalence in the table is defined as a person with epilepsy who has had at least two unprovoked seizures on different days in the 
previous year, regardless of antiepileptic drug (AED) treatment. 
Common-1: The diagnosis of epilepsy: 1) the condition must be characterized by two or more unprovoked epileptic seizures; 2) individuals with 
febrile seizures were excluded. 
Common-2: The diagnosis of epilepsy: 1) the condition must be characterized by two or more unprovoked epileptic seizures; 2) individuals with 






Ren et al.(2007)40 Yunnan 2005 4465 rural WHO&ICBEGR 
SQ 
common-2 all 3.58 2.69 22.39 
Yu et al.(2009)41 Yunnan 2007-2008 10579 rural WHO&ICBEGR 
SQ 
ILAE 1989 all 1.80 1.51 18.99 
Meng et al.(2010)42 Jilin 2008 310402 rural NS ILAE 1981 all 3.94 NS 22.55 
Li et al(2012)43 Hebei 2008-2010 20138 rural WHO&ICBEGR 
SQ 
common-2 all 6.85 4.9 26.9 




ILAE 1993 all 4.5 2.8 NS 
Li et al.(2014)45 Gansu 2010-2011 2533500 rural SQ common-1 convuls
ive 
1.59 NS NS 
Song et al.(2012)46 Shandong 2011 850900 rural SQ common-1 convuls
ive 
0.75 0.23 4.94 












2012-2013 16873 rural WHO&ICBEGR 
SQ 
ILAE1993 all 3.97 NS NS 
Without recorded mass in- and out-migration or major demographic alteration in 
the population structure, life-time prevalence is determined by the rate at which new 
cases arise and the rate at which existing cases die.1 The "Global Campaign against 
Epilepsy demonstration project" was launched in China in 2000. Over more than a 
decade, this project was effective and made a difference to epilepsy care in China, 
especially in rural areas.15 As well as benefits brought by economic growth, swift 
urbanization and healthcare improvement, some well-documented risk factors, such as 
consanguineous marriage, febrile seizures, prenatal and perinatal central nervous 
system deficits and infections, may have decreased in China.19–21 These could account 
for a decrease in the incidence of epilepsy. 
As shown in the incidence-prevalence-mortality model in Figure 3, irrespective of 
mortality, life-time prevalence should increase with age, or remain unchanged if the 
incidence is zero (Figure 3A). When the death rate is higher than the incidence rate, 
the prevalence rate decreases (Figure 3B). The discrepancy in prevalence rates at 
different time points in the same areas highlights the importance of taking premature 
mortality into account. Generally, epilepsy mortality rates are considered to be 1.3 to 
9.3 fold higher than in the general population and this could be even higher in poor-
settings.22–24 Anecdotal evidence from high-income countries suggests that a potential 
reason for few older people with a life history of epilepsy being seen in epilepsy 
clinics is premature death,5 although cerebrovascular disease and trauma are potential 
risk factors in older adults.25,26 It has been suggested that a higher mortality rate in 
low-and middle- income countries may explain the discrepancy between high 
incidence and relatively low prevalence.5,27 A small study in rural Laos, with an 
estimated prevalence of 7.7‰, found that almost one in nine people with epilepsy 
died within a short period.28 In China, a cohort study reported that around one fifth 
died over a 12 years period.29 Long-term follow-up of cohorts found premature 
mortality was higher in people with epilepsy than in the general population and much 
higher in young people.30,31 Sudden unexpected death in epilepsy, an important cause 
of premature mortality in people with epilepsy, was estimated to have higher 
incidence in China than in high-income countries.32 We hypothesize that the 
decreasing life-time prevalence we found is attributed to a combination of a lower 
incidence rate and higher premature mortality. Effective ways should be implemented 
to reduce premature mortality. 
Our study has limitations. Firstly, although highly specific and sensitive screening 
tools and strict diagnostic procedures were used, epilepsy is a condition with a long 
history of stigma and discrimination influencing individuals’ attitude toward 
disclosure of a diagnosis, so epilepsy prevalence might have been underestimated. 
Using an identical survey protocol, in the same general survey areas, however, and 
with no evidence of increasing concealment, we found a difference in the two surveys. 
Secondly, compared to the 2000-2002 survey, the sample size of the 2010-2013 
survey was smaller; it was, however, large enough to obtain an adequate cross-
sectional prevalence based on the sample size calculation. Thirdly, data in the surveys 
may not fully reflect the overall Chinese situation. Nevertheless, our target areas 
represented rural and urban areas of China. Fourthly, there is incomplete overlap of 
the surveyed population at the two time points. The target survey populations are, 
however, in adjacent areas receiving the same level of care and having subjects with 
similar social and demographic changes over the time period. Lastly, the lack of 
datasets of concurrent active prevalence, incidence, mortality and treatment gap 
hinder us from analyzing the change in the full epilepsy burden in China. 
Our findings differ from the recognized upward trend in life-time epilepsy 
prevalence. Epilepsy seems to be decreasing in China, but we suspect it may be 
related to decreased incidence and increased premature mortality. High-quality, large-
sample, multi-center epidemiological surveys collecting concurrent data on incidence, 
prevalence, mortality in low- and middle- income countries are warranted to confirm a 
change in the epilepsy burden. 
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